Vivus (and other obesity stocks) slims down after Qsymia flop
This article was originally published in Scrip
With Qsymia (topiramate and phentermine) generating just $2 million in sales between its September launch and the end of 2012, Vivus' stock has fallen to nearly one-third of the $29 price it achieved after US FDA approval of its weight loss drug seven months ago.
You may also be interested in...
Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.
Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.
Public Company Edition: Moderna leveraged its all-time high stock price to raise $1.34bn on the same day it reported data from a Phase I trial of its COVID-19 vaccine. Several other companies also took advantage of biopharma’s rising value.